Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Neoplasm|ATM Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Metastatic Malignant Neoplasm|PALB2 Gene Mutation|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm
Interventions: OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Talazoparib
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)